JAC Advance Access originally published online on February 4, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 435-440
© 2004 The British Society for Antimicrobial Chemotherapy
Anti-staphylococcal activity and mode of action of clofazimine
1 Department of Experimental Medicine, University of L’Aquila, Coppito-67100, L’Aquila, Italy; 2 Antimicrobial Research Centre and Division of Microbiology, School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT, UK
Received 27 August 2003; returned 8 December 2003; revised 15 December 2003; accepted 16 December 2003
Objectives: Infections caused by Staphylococcus aureus might be treated with agents whose primary indications are for other infections. Clofazimine, an established anti-mycobacterial drug, could be such a candidate. However, the anti-staphylococcal properties of clofazimine have not been fully described and its mode of action, possibly involving inhibition of both RNA polymerase and a membrane-located target, has not been explored in detail. We have now conducted experiments to address these issues.
Methods: Using established procedures, we examined the activity of clofazimine against a range of clinical isolates of S. aureus and determined whether it was bactericidal, exhibited a post-antibiotic effect (PAE), or interacted synergically with other agents. The potential for emergence of clofazimine-resistant mutants was also examined. Mode of action studies involved macromolecular synthesis assays, cross-screening against rifampicin-resistant mutants, susceptibility of RNA polymerase to clofazimine in vitro and several methods to detect drug-induced membrane damage.
Results: Clofazimine demonstrated good anti-staphylococcal activity encompassing MSSA, MRSA and GISA. It was bactericidal and resistant mutants could not be isolated. Clofazimine did not exhibit a PAE and failed to act synergically with other drugs. No evidence for specific inhibition of RNA polymerase was obtained. Clofazimine caused non-specific inhibition of DNA, RNA and protein synthesis, consistent with membrane-damaging activity that was detected in three independent assays for membrane disrupting agents.
Conclusions: Clofazimine is a potent anti-staphylococcal agent. It appears to be a membrane-disrupting agent and does not inhibit RNA polymerase.
Keywords: Staphylococcus aureus, mechanisms of antibiotic action, membrane-disrupting agent
* Corresponding author. Tel: +44-113-233-5604; Fax: +44-113-233-5638; E-mail: i.chopra{at}leeds.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. G. Hurdle, R. Yendapally, D. Sun, and R. E. Lee Evaluation of Analogs of Reutericyclin as Prospective Candidates for Treatment of Staphylococcal Skin Infections Antimicrob. Agents Chemother., September 1, 2009; 53(9): 4028 - 4031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Cholo, H. I. Boshoff, H. C. Steel, R. Cockeran, N. M. Matlola, K. J. Downing, V. Mizrahi, and R. Anderson Effects of clofazimine on potassium uptake by a Trk-deletion mutant of Mycobacterium tuberculosis J. Antimicrob. Chemother., January 1, 2006; 57(1): 79 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. O'Neill, K. Miller, B. Oliva, and I. Chopra Comparison of assays for detection of agents causing membrane damage in Staphylococcus aureus J. Antimicrob. Chemother., December 1, 2004; 54(6): 1127 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Stubbings, J. M. Bostock, E. Ingham, and I. Chopra Assessment of a microplate method for determining the post-antibiotic effect in Staphylococcus aureus and Escherichia coli J. Antimicrob. Chemother., July 1, 2004; 54(1): 139 - 143. [Abstract] [Full Text] [PDF]
|
|